AB001 ARTISAN dose-escalation data
ARTISAN evaluates a lead-212 PSMA-targeted alpha radioligand in metastatic castration-resistant prostate cancer. ARTBIO announced dosing of Lu-177-PSMA-naive and experienced cohorts in January 2026.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Keep prior Lu-177 treatment groups distinct and predefine whether pooled data qualifies.
- Research candidate, not a live market, clinical probability, company equity or access to private shares.
Primary evidence
Phase 1 readout — date unconfirmed
Company context
Company-authored LinkedIn About explicitly states Type: Privately Held and links artbio.com. Opened and checked October 31, 2026. This is an undated company self-report, not independent registry proof. Its investor Sofinnova also lists Status Private, but company self-report is the classification source here.
Potential outcome market
Will ARTBIO publicly report dose-escalation safety and antitumor results from ARTISAN by the market deadline?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.